Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological aggressiveness
BJS Open · 2025
DOI: 10.1093/bjsopen/zraf033 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift BJS Open, 2025. Verfasst von Giulio Belfiori und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pancreatic Surgery, Pancreas Translational & Clinical Research Centre, IRCCS San Raffaele Scientific Institute, Milan, Italy. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Pancreatectomy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Nadia Valsecchi, Italian Association for Cancer Research.
Abstract (Originalsprache)
Background
The anatomically resectable pancreatic ductal adenocarcinoma treatment sequence is still debated. Heterogeneity in patient characteristics within this group may explain literature discrepancies. To overcome these limits, a biologically borderline resectable pancreatic ductal adenocarcinoma category has been analysed according to institutional criteria. The aim of this study was to examine the characteristics and outcomes of patients with biologically borderline resectable pancreatic ductal adenocarcinoma and determine whether they represent a distinct clinical and prognostic subgroup.
Methods
Data from all consecutive patients who underwent surgical resection for pancreatic ductal adenocarcinoma between 2015 and 2022 were retrospectively analysed. Biologically borderline resectable disease was classified by the presence of one or more of the following: carbohydrate antigen 19-9 ≥200 U/ml, cancer-related symptoms lasting >40 days, and radiological suspicion of regional lymph node metastases at diagnosis.
Results
In total, 886 patients were included in the study and divided into anatomically borderline resectable (266 patients (30%)) and anatomically resectable (620 patients (70%)), which was further divided into resectable (R; 397 patients (64%)) and biologically borderline resectable (223 patients (36%)). Neoadjuvant treatment was administered in 245 patients (92.1%) in the anatomically borderline resectable group, 82 patients (20.7%) in the R group, and 135 patients (60.5%) in the biologically borderline resectable group. After a median follow-up of 45 (95% c.i. 42 to 48) months, the median disease-specific survival in the biologically borderline resectable group was 40 months compared with 59 months in the R group (P < 0.001) and 40 months in the anatomically borderline resectable group (P = 0.570). In the upfront surgery cohort, the median disease-specific survival was worse for biologically borderline resectable patients compared with R patients (27 versus 54 months respectively, P < 0.001). Biologically borderline resectable was also independently associated with worse disease-specific survival, together with age, tumour size at diagnosis, and anatomically borderline resectable. The same, except for age, were also predictors of worse event-free survival.
Conclusion
Despite their identical anatomical appearance, resectable and biologically borderline resectable pancreatic ductal adenocarcinoma represent two distinct prognostic entities, warranting separate evaluation and, potentially, different treatment approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pancreatic Surgery, Pancreas Translational & Clinical Research Centre, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Department of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Department of Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
ORCID-Profile: Domenico Tamburrino, Nicolo Pecorelli, Diego Palumbo, Stefano Partelli, Michele Reni
Förderung
- Fondazione Nadia Valsecchi
- Italian Association for Cancer Research
Zitieren
APA
Belfiori, G., De Stefano, F., Tamburrino, D., Gasparini, G., Aleotti, F., Camisa, P. R., Arcangeli, C., Schiavo Lena, M., Pecorelli, N., Palumbo, D., Partelli, S., De Cobelli, F., Reni, M., Crippa, S., & Falconi, M. (2025). Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological aggressiveness. BJS Open. https://doi.org/10.1093/bjsopen/zraf033
Vancouver
Belfiori G, De Stefano F, Tamburrino D, Gasparini G, Aleotti F, Camisa PR, et al. Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological aggressiveness. BJS Open. 2025. doi:10.1093/bjsopen/zraf033
BibTeX
@article{Belfiori2025,
author = {Belfiori, Giulio and De Stefano, Federico and Tamburrino, Domenico and Gasparini, Giulia and Aleotti, Francesca and Camisa, Paolo R and Arcangeli, Claudia and Schiavo Lena, Marco and Pecorelli, Nicolo and Palumbo, Diego and Partelli, Stefano and De Cobelli, Francesco and Reni, Michele and Crippa, Stefano and Falconi, Massimo},
title = {Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological aggressiveness},
journal = {BJS Open},
year = {2025},
doi = {10.1093/bjsopen/zraf033}
}
EUVIMED